Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

OBJECTIVE: To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-LN trial (NCT02547922) of 2 anifrolumab dosing regimens versus placebo. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayne, David, Rovin, Brad, Mysler, Eduardo, Furie, Richard, Houssiau, Frédéric, Trasieva, Teodora, Knagenhjelm, Jacob, Schwetje, Erik, Tang, Weifeng, Tummala, Raj, Lindholm, Catharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Lupus Nephritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445374/
https://www.ncbi.nlm.nih.gov/pubmed/37607780
http://dx.doi.org/10.1136/lupus-2023-000910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445374/
https://www.ncbi.nlm.nih.gov/pubmed/37607780
http://dx.doi.org/10.1136/lupus-2023-000910

Ejemplares similares